Skip to content
Descubridor Institucional UMAR
Inicio
Búsqueda avanzada
Explorar
Inicio
Búsqueda avanzada
Explorar
Login
Language
English
Deutsch
Español
Français
Italiano
All Fields
Title
Author
Subject
Call Number
ISBN/ISSN
Tag
Find
Advanced
Model‐Based Benefit/Risk Analysis for the Copanlisib Intermittent Dosing Regimen
Model‐Based Benefit/Risk Analysis for the Copanlisib Intermittent Dosing Regimen
Fuente:
Wiley Open Access
Saved in:
Bibliographic Details
Main Authors:
Peter N. Morcos
,
Jonathan Moss
,
Josh Veasy
,
Florian Hiemeyer
,
Barrett H. Childs
,
Dirk Garmann
Format:
Artículo Open Access
Published:
Wiley
2024
Subjects:
Clinical Pharmacology & Therapeutics
Online Access:
Acceder al recurso
Tags:
Add Tag
No Tags, Be the first to tag this record!
Cite this
Text this
Email this
Print
Export Record
Export to RefWorks
Export to EndNoteWeb
Export to EndNote
Save to List
Permanent link
Holdings
Description
Comments
Similar Items
Staff View
Internet
https://ascpt.onlinelibrary.wiley.com/doi/10.1002/cpt.3173
Similar Items
A Novel Step‐Up Dosage Regimen for Enhancing the Benefit‐to‐Risk Ratio of Mosunetuzumab in Relapsed or Refractory Follicular Lymphoma
by: Chi‐Chung Li, et al.
Published: (2024)
Real‐World Edoxaban Concentrations in Older Patients Receiving Reduced‐Dose Regimens
by: Sung‐Chun Tang, et al.
Published: (2025)
Optimizing Maternal and Fetal Antibody Exposure and Dosing Regimens During Pregnancy Using a Physiologically Based Pharmacokinetic Model
by: Miramar Sami Kardouh, et al.
Published: (2025)
Model‐Informed Approach to Recommend Burosumab Dosing Regimens for Pediatric and Adult Patients With the Ultrarare Disease Tumor‐Induced Osteomalacia
by: Matthew W. Hruska, et al.
Published: (2024)
Viral Kinetics Model of SARS‐CoV‐2 Infection Informs Drug Discovery, Clinical Dose, and Regimen Selection
by: Allison M. Claas, et al.
Published: (2024)